Targeted therapies in systemic lupus erythematosus

Lupus

Volumn 22, Issue 10, 2013, Pages 978-986

  Grech, P ^a   Khamashta, M A ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

anti DNA antibodies; B cells; biological therapies; Systemic lupus erythematosus; treatment

Indexed keywords

ABATACEPT; ATACICEPT; BELIMUMAB; CORTICOSTEROID; EPRATUZUMAB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OCRELIZUMAB; PLACEBO; RITUXIMAB; RONTALIZUMAB; SIFALIMUMAB; TOCILIZUMAB;

ALLERGIC REACTION; CORTICOSTEROID THERAPY; DISEASE ACTIVITY; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; NEOPLASM; NEUTROPENIA; OFF LABEL DRUG USE; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT RESPONSE; VIRUS INFECTION;

ANTI-DNA ANTIBODIES; B CELLS; BIOLOGICAL THERAPIES; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CLINICAL TRIALS AS TOPIC; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 84882975656     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203313499417     Document Type: Review

References (57)

1. Pons-Estel GJ, Alarcón GS, Scofield L, Reinlib L, Cooper GS. Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum. 2010 ; 39: 257-268
2. Cervera R, Khamashta MA, Font J, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: A comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore). 2003 ; 82: 299-308
3. Munoz LE, Gaipl US, Franz S, et al. SLE - a disease of clearance deficiency?. Rheumatology (Oxford). 2005 ; 44: 1101-1107
4. Bertsias GK, Salmon JE, Boumpas DT. Therapeutic opportunities in systemic lupus erythematosus: State of the art and prospects for the new decade. Ann Rheum Dis. 2010 ; 69: 1603-1611
5. Kimberly RP. Immune complexes in the rheumatic diseases. Rheum Dis Clin North Am. 1987 ; 13: 583-596
6. Trager J, Ward MM. Mortality and causes of death in systemic lupus erythematosus. Curr Opin Rheumatol. 2001 ; 13: 345-351
7. Yildirim-Toruner C, Diamond B. Current and novel therapeutics in the treatment of systemic lupus erythematosus. J Allergy Clin Immunol. 2011 ; 127: 303-312
8. US Food and Drug Administration. FDA approves Benlysta to treat lupus. http://www.fda.gov/newsevents/newsroom/pressAnnouncements/ucm246489.htm (2011, accessed 7 November 2012).
9. European Medicines Agency. Assessment report: Benlysta, http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Public-assessment- report/human/002015/WC500110152.pdf (2011, accessed November 2012).
10. Dennis GJ. Belimumab: A BLyS-specific inhibitor for the treatment of systemic lupus erythematosus. Clin Pharmacol Ther. 2012 ; 91: 143-149
11. Stohl W, Metyas S, Tan SM, et al. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: Longitudinal observations. Arthritis Rheum. 2003 ; 48: 3475-3486
12. Mackay F, Schneider P. Cracking the BAFF code. Nat Rev Immunol. 2009 ; 9: 491-502
13. Ramos-Casals M, Sanz I, Bosch X, Stone JH, Khamashta MA. B-cell-depleting therapy in systemic lupus erythematosus. Am J Med. 2012 ; 125: 327-336
14. Wallace DJ, Stohl W, Furie RA, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 2009 ; 61: s1168 - s1178
15. Furie R, Petri MA, Wallace DJ, et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum. 2009 ; 61: 1143-1151
16. Navarra SV, Guzmán RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial. Lancet. 2011 ; 377: 721-731
17. Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011 ; 63: 3918-3930
18. Wallace DJ, Navarra S, Petri M, et al. Safety profile of belimumab, a B-lymphocyte stimulator-specific inhibitor, in phase 2 and 3 clinical trials of patients with active systemic lupus erythematosus. In: ACR/ARHP Scientific Annual Scientific Meeting, Chicago, IL, USA, 6 November 2011, presentation number 578.
19. Manzi S, Sánchez-Guerrero J, Merrill JT, et al. BLISS-52 and BLISS-76 Study Groups. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis 2012; 71: 1833-1838.
20. Pena-Rossi C, Nasonov E, Stanislav M, et al. An exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus. Lupus. 2009 ; 18: 547-555
21. Ginzler EM, Wax S, Rajeswaran A, et al. Atacicept in combination with MMF and corticosteroids in lupus nephritis: Results of a prematurely terminated trial. Arthritis Res Ther. 2012 ; 14: R33 - R33
22. Lo MS, Tsokos GC. Treatment of systemic lupus erythematosus: New advances in targeted therapy. Ann N Y Acad Sci. 2012 ; 1247: 138-152
23. Taylor RP, Lindorfer MA. Drug insight: The mechanism of action of rituximab in autoimmune disease - the immune complex decoy hypothesis. Nat Clin Pract Rheumatol. 2007 ; 3: 86-95
24. Anolik JH, Campbell D, Felgar RE, et al. The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum. 2003 ; 48: 455-459
25. Ramos-Casals M, Soto MJ, Cuadrado MJ, Khamashta MA. Rituximab in systemic lupus erythematosus: A systematic review of off-label use in 188 cases. Lupus. 2009 ; 18: 767-776
26. Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010 ; 62: 222-233
27. Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 2012 ; 64: 1215-1226
28. Ramos-Casals M, Díaz-Lagares C, Khamashta MA. Rituximab and lupus: Good in real life, bad in controlled trials. Comment on the article by Lu et al. Arthritis Rheum. 2009 ; 61: 1281-1282
29. Merrill J, Buyon J, Furie R, et al. Assessment of flares in lupus patients enrolled in a phase II/III study of rituximab (EXPLORER). Lupus. 2011 ; 20: 709-716
30. US Food and Drug Administration. Public Health Advisory: Life-threatening brain infection in patients with systemic lupus erythematosus after rituxan (rituximab) treatment. http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm124345. htm (2006, accessed 14 November 2012).
31. Molloy ES, Calabrese LH. Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: Are patients with systemic lupus erythematosus at particular risk?. Autoimmun Rev. 2008 ; 8: 144-146
32. Mysler EF, Spindler AJ, Guzman R, et al. Efficacy and safety of ocrelizumab, a humanized antiCD20 antibody, in patients with active proliferative lupus nephritis (LN): results from the randomized, double-blind phase III BELONG study. Arthritis Rheum 2010; 62: 1455.
33. Murdaca G, Colombo BM, Puppo F. Emerging biological drugs: a new therapeutic approach for Systemic Lupus Erythematosus. An update upon efficacy and adverse events. Autoimmun Rev 2011; 11: 56-60.
34. Petri M, Hobbs K, Gordon C, et al. Randomized controlled trials (RCTS) of epratuzumab (anti-CD22 mAb targeting B-cells) reveal clinically meaningful improvements in patients (pts) with moderate/severe SLE flares [OP-0016]. Ann Rheum Dis 2008; 67: 53.
35. Wallace DJ. Epratuzumab (anti-CD22 mAb targeting B cells) provides clinically meaningful reductions in corticosteroids (CS) use with a favourable safety profile in patients with moderate/severe flaring SLE: results from randomised controlled trials (RCTs). Arthritis Rheum 2008; 57: 1088.
36. Wallace DJ, Kalunian K, Petri MA, et al. Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. Ann Rheum Dis 2013 (in press).
37. Yazdany J, Davis J. The role of CD40 ligand in systemic lupus erythematosus. Lupus. 2004 ; 13: 377-380
38. Koshy M, Berger D, Crow MK. Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes. J Clin Invest. 1996 ; 98: 826-837
39. Boumpas DT, Furie R, Manzi S, et al. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum. 2003 ; 48: 719-727
40. Robles-Carrillo L, Meyer T, Hatfield M, et al. Anti-CD40L immune complexes potently activate platelets in vitro and cause thrombosis in FCGR2A transgenic mice. J Immunol. 2010 ; 185: 1577-1583
41. Merrill JT, Burgos-Vargas R, Westhovens R, et al. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: Results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010 ; 62: 3077-3087
42. Furie R, Nicholls K, Cheng TT, et al. Efficacy and safety of abatacept over 12 months in patients with lupus nephritis: Results from a multicenter, randomized, double-blind, placebo-controlled phase II/III study. Arthritis Rheum. 2011 ; 63: 2469-2469
43. Daikh DI, Wofsy D. Cutting edge: Reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide. J Immunol. 2001 ; 166: 2913-2916
44. Wofsy D, Hillson JL, Diamond B. Abatacept for lupus nephritis: Alternative definitions of complete response support conflicting conclusions. Arthritis Rheum. 2012 ; 64: 3660-3665
45. Tackey E, Lipsky PE, Illei GG. Rationale for interleukin-6 blockade in systemic lupus erythematosus. Lupus. 2004 ; 13: 339-343
46. Iwano M, Dohi K, Hirata E, et al. Urinary levels of IL-6 in patients with active lupus nephritis. Clin Nephrol. 1993 ; 40: 16-21
47. Illei GG, Shirota Y, Yarboro CH, et al. Tocilizumab in systemic lupus erythematosus: Data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum. 2010 ; 62: 542-552
48. Baechler EC, Batliwalla FM, Karypis G, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A. 2003 ; 100: 2610-2615
49. Lichtman EI, Helfgott SM, Kriegel MA. Emerging therapies for systemic lupus erythematosus - focus on targeting interferon-alpha. Clin Immunol. 2012 ; 143: 210-221
50. Yan B, Ye S, Chen G, Kuang M, Shen N, Chen S. Dysfunctional CD4+,CD25+ regulatory T cells in untreated active systemic lupus erythematosus secondary to interferon-alpha-producing antigen-presenting cells. Arthritis Rheum. 2008 ; 58: 801-812
51. Garcia-Romo GS, Caielli S, Vega B, et al. Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci Transl Med. 2011 ; 3: 73ra20-73ra20
52. Merrill JT, Wallace DJ, Petri M, et al. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: A phase I, multicentre, double-blind randomised study. Ann Rheum Dis. 2011 ; 70: 1905-1913
53. McBride JM, Jiang J, Abbas AR, et al. Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study. Arthritis Rheum 2012; 64: 3666-3676.
54. Greth W. A study to evaluate the efficacy and safety of sifalimumab in adults. http://clinicaltrials.gov/show/NCT01283139 (2012, accessed 20 November 2012).
55. Kennedy. A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus (ROSE). http://clinicaltrials.gov/show/NCT00962832 (2013, accessed 2 June 2013).
56. Crispín JC, Tsokos GC. Novel molecular targets in the treatment of systemic lupus erythematosus. Autoimmun Rev. 2008 ; 7: 256-261
57. Deng GM, Liu L, Bahjat FR, Pine PR, Tsokos GC. Suppression of skin and kidney disease by inhibition of spleen tyrosine kinase in lupus-prone mice. Arthritis Rheum. 2010 ; 62: 2086-2092